The trial was a collaborative effort involving Sidra Medicine’s Endocrinology and Clinical Trials Program and several internal departments. Credit: Sidra Medicine.

Qatar Foundation member Sidra Medicine has conducted the industry-sponsored ‘sunRIZE’ trial for paediatric congenital hyperinsulinism.

The first pharmaceutical trial comes after Sidra launched the ‘Clinical Trials Program’, which aims to advance treatment options for rare and complex conditions in the Arab region.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

The Phase III sunRIZE trial is led by biopharmaceutical company Rezolute.

Sidra Medicine, selected as one of 22 leading sites globally for the trial, is currently recruiting more subjects aged between three months and 18 years.

The trial, which received approval from Qatar’s Ministry of Public Health, was a collaborative effort involving Sidra Medicine’s Endocrinology and Clinical Trials Program and several internal departments including the Institutional Review Board, IT, pharmacy, and nursing.

Sidra Medicine Endocrinology division chief professor Khalid Hussain said: “This clinical trial represents a pivotal step in advancing care for congenital hyperinsulinism. Phase III trials compare new treatments to existing options in a diverse and larger patient population, providing evidence for regulatory approval based on effectiveness and safety.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

“Our collaboration with Rezolute and international experts aims to develop a safer, non-invasive treatment option that could transform the lives of affected children and significantly reduce the need for surgery.”

Sidra Medicine is also focusing on other disorders, including neuromuscular conditions, metabolic disorders, and paediatric cancers.

Earlier this year, it announced a protocol for treating a young Kuwaiti patient with congenital hyperinsulinism.

Congenital hyperinsulinism, a condition causing dangerous hypoglycaemia due to excessive insulin production, often leaves children unresponsive to current therapies and undergo invasive surgeries.

Sidra Medicine clinical trials office manager Dr Antonella Cioce said: “This clinical trial highlights the exceptional teamwork and dedication at Sidra Medicine in advancing therapies for rare paediatric conditions.

“The trial represents a significant step toward transforming the care and outcomes for children with congenital hyperinsulinism, offering the potential to redefine treatment standards and bring hope to patients locally and globally.”